{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Hepatitis B virus", "In silico analysis", "Medical plant", "Molecular docking"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "30607323", "DateRevised": {"Year": "2020", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "05", "Day": "17"}], "Language": ["eng"], "ELocationID": ["10", "10.1007/s40203-018-0047-3"], "Journal": {"ISSN": "2193-9616", "JournalIssue": {"Volume": "6", "Issue": "1", "PubDate": {"Year": "2018"}}, "Title": "In silico pharmacology", "ISOAbbreviation": "In Silico Pharmacol"}, "ArticleTitle": "Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study.", "Pagination": {"StartPage": "10", "MedlinePgn": "10"}, "Abstract": {"AbstractText": ["Hepatitis B virus (HBV) infects more than 400 million humans Worldwide. Currently, development of new anti-HBV agents is focused on inhibiting of HBV DNA polymerase activity. The natural components of medicinal plant have a broad spectrum of biological activities with therapeutic properties which can be exploited in various steps of drug discovery. Currently, in silico analyses have been introduced as alternative or supplements methods for drug discovery. This study was planned to in silico screening novel HBV DNA polymerase inhibitor(s) from <i>R. palmatum</i>, <i>R. coreanus</i> and <i>S. officinalis</i>. For this purpose, a set of dominant phytochemicals from mentioned plants were retrieved from PubChem database and primary screening was performed with molecular docking method using iGemdock 2.1 software. SwissADME and MedChem Designer 3.0 were used to calculate the drug-likeness parameters of the ligands. Furthermore, the genotoxicity of the studied ligands was predicted using Toxtree 2.6.6 software. Final analysis of screened compounds was done using Autodock 4 software. Result confirmed that Frangulosid and Lindleyin acid have most and least efficacy in HBV DNA polymerase inhibition with the inhibition constant of 2.97 and 53.83\u00a0\u00b5M, respectively. Results also showed that, the amino acids, involved in interaction, were different for each compound. In this regards, results revealed that the main amino acids residues of the receptor, involved in interaction with Quercetin-3-glucuronide, Frangulosid and Lindleyin separately, located in 420-424, 606-615 and 512-542 spectra, respectively. In conclusion, Frangulosid can be considered as a good candidate for more investigation of its anti-HBV activity."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": ["0000 0001 0454 365X", "grid.411750.6"], "Affiliation": "1Department of Biotechnology, Faculty of Advanced Science and Technologies, University of Isfahan, Isfahan, Iran."}], "LastName": "Nosrati", "ForeName": "Mokhtar", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["0000 0001 0454 365X", "grid.411750.6"], "Affiliation": "1Department of Biotechnology, Faculty of Advanced Science and Technologies, University of Isfahan, Isfahan, Iran."}], "LastName": "Shakeran", "ForeName": "Zahra", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["0000 0001 0454 365X", "grid.411750.6"], "Affiliation": "2Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran."}], "LastName": "Shakeran", "ForeName": "Zainab", "Initials": "Z"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "In Silico Pharmacol", "NlmUniqueID": "101623954", "ISSNLinking": "2193-9616"}, "CoiStatement": "Compliance with ethical standardsThe authors have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Ahmad A, Ahad A, Rao AQ, Husnain T. Molecular docking based screening of neem-derived compounds with the NS1 protein of Influenza virus. Bioinformation. 2015;11:359. doi: 10.6026/97320630011359.", "ArticleIdList": ["10.6026/97320630011359", "PMC4546996", "26339153"]}, {"Citation": "Bonif\u00e1cio BV, da Silva PB, dos Santos Ramos MA, Negri KMS, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomed. 2014;9:1. doi: 10.2217/nnm.13.186.", "ArticleIdList": ["10.2217/nnm.13.186", "PMC3862741", "24363556"]}, {"Citation": "Byler KG, Ogungbe IV, Setzer WN. In-silico screening for anti-Zika virus phytochemicals. J Mol Graph Model. 2016;69:78\u201391. doi: 10.1016/j.jmgm.2016.08.011.", "ArticleIdList": ["10.1016/j.jmgm.2016.08.011", "PMC7185537", "27588363"]}, {"Citation": "Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286:52\u201359. doi: 10.1016/j.canlet.2008.12.003.", "ArticleIdList": ["10.1016/j.canlet.2008.12.003", "19147276"]}, {"Citation": "Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) J Virol. 2001;75:4771\u20134779. doi: 10.1128/JVI.75.10.4771-4779.2001.", "ArticleIdList": ["10.1128/JVI.75.10.4771-4779.2001", "PMC114232", "11312349"]}, {"Citation": "Dibyajyoti S, Bin ET, Swati P. Bioinformatics: the effects on the cost of drug discovery. Galle Med J. 2013;18:44\u201350. doi: 10.4038/gmj.v18i1.5511.", "ArticleIdList": ["10.4038/gmj.v18i1.5511"]}, {"Citation": "Ganem D, Prince AM. Hepatitis B virus infection\u2014natural history and clinical consequences. N Engl J Med. 2004;350:1118\u20131129. doi: 10.1056/NEJMra031087.", "ArticleIdList": ["10.1056/NEJMra031087", "15014185"]}, {"Citation": "Jain J, Kumari A, Somvanshi P, Grover A, Pai S, Sunil S. In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus. F1000Research. 2017;6:1601. doi: 10.12688/f1000research.12301.1.", "ArticleIdList": ["10.12688/f1000research.12301.1", "PMC5747330", "29333236"]}, {"Citation": "Jones SA, Clark DN, Cao F, Tavis JE, Hu J. Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming. J Virol. 2014;88:1564\u20131572. doi: 10.1128/JVI.02852-13.", "ArticleIdList": ["10.1128/JVI.02852-13", "PMC3911602", "24227865"]}, {"Citation": "Kandagalla S, Sharath B, Bharath BR, Manjunatha H. Molecular docking analysis of curcumin analogues against kinase domain of ALK5. In Silico Pharmacol. 2016;5:15. doi: 10.1007/s40203-017-0034-0.", "ArticleIdList": ["10.1007/s40203-017-0034-0", "PMC5755696", "29308351"]}, {"Citation": "Khan MTH, Ather A, Thompson KD, Gambari R. Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res. 2005;67:107\u2013119. doi: 10.1016/j.antiviral.2005.05.002.", "ArticleIdList": ["10.1016/j.antiviral.2005.05.002", "16040137"]}, {"Citation": "Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH. Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res. 2001;15:718\u2013720. doi: 10.1002/ptr.832.", "ArticleIdList": ["10.1002/ptr.832", "11746867"]}, {"Citation": "Kim K-H, Kim ND, Seong B-L. Discovery and development of anti-HBV agents and their resistance. Molecules. 2010;15:5878\u20135908. doi: 10.3390/molecules15095878.", "ArticleIdList": ["10.3390/molecules15095878", "PMC6257723", "20802402"]}, {"Citation": "Kurokawa M, et al. Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica In vitro and in vivo. J Pharmacol Exp Ther. 1999;289:72\u201378.", "ArticleIdList": ["10086989"]}, {"Citation": "Langley DR, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81(8):3992\u20134001. doi: 10.1128/JVI.02395-06.", "ArticleIdList": ["10.1128/JVI.02395-06", "PMC1866160", "17267485"]}, {"Citation": "Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis. 2004;11:97\u2013107. doi: 10.1046/j.1365-2893.2003.00487.x.", "ArticleIdList": ["10.1046/j.1365-2893.2003.00487.x", "14996343"]}, {"Citation": "Lin X, Zhang S, Huang Q, Zheng L, Huang J, Zhang X, Huang R. Anti-hepatitis B virus activity of total saponins isolated from Taraphochlamys affinis in vitro and in vivo. J Med Plants Res. 2013;7:2841\u20132846."}, {"Citation": "Lok AS, McMahon BJ. Chronic hepatitis B: update. Hepatology. 2009;50:661\u2013662. doi: 10.1002/hep.23190.", "ArticleIdList": ["10.1002/hep.23190", "19714720"]}, {"Citation": "Lu F, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl) 2009;122:3\u20134.", "ArticleIdList": ["19187608"]}, {"Citation": "Mak L-Y, Seto W-K, Lai C-L, Yuen M-F. DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. Expert Opin Drug Saf. 2016;15:383\u2013392. doi: 10.1517/14740338.2016.1139573.", "ArticleIdList": ["10.1517/14740338.2016.1139573", "26752687"]}, {"Citation": "Mekha Mohan PJ, Valsalan R, Nazeem PA. Molecular docking studies of phytochemicals from Phyllanthus niruri against hepatitis B DNA polymerase. Bioinformation. 2015;11:426. doi: 10.6026/97320630011426.", "ArticleIdList": ["10.6026/97320630011426", "PMC4620619", "26527851"]}, {"Citation": "Meng F-C, Xu W-R, Li Y-Z, Huang Z-M, Liang G-Y, Liu C-X. In silico molecular docking study of repensine and bentysrepinine against HBV DNA polymerase. Chin Herb Med. 2015;7:39\u201344. doi: 10.1016/S1674-6384(15)60018-1.", "ArticleIdList": ["10.1016/S1674-6384(15)60018-1"]}, {"Citation": "Michel M-L, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011;54(6):1286\u20131296. doi: 10.1016/j.jhep.2010.12.031.", "ArticleIdList": ["10.1016/j.jhep.2010.12.031", "21238516"]}, {"Citation": "Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, Parveen Z. Antiviral potentials of medicinal plants. Virus Res. 2008;131:111\u2013120. doi: 10.1016/j.virusres.2007.09.008.", "ArticleIdList": ["10.1016/j.virusres.2007.09.008", "PMC7114233", "17981353"]}, {"Citation": "Muzaffer U, Paul V, Prasad NR. Molecular docking of selected phytoconstituents with signaling molecules of ultraviolet-B induced oxidative damage. In Silico Pharmacol. 2016;5:17. doi: 10.1007/s40203-017-0035-z.", "ArticleIdList": ["10.1007/s40203-017-0035-z", "PMC5755689", "29308353"]}, {"Citation": "Nassal M, Schaller H. Hepatitis B virus replication. Trends Microbiol. 1993;1:221\u2013228. doi: 10.1016/0966-842X(93)90136-F.", "ArticleIdList": ["10.1016/0966-842X(93)90136-F", "8137119"]}, {"Citation": "Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594\u2013604. doi: 10.1016/j.jhep.2009.10.033.", "ArticleIdList": ["10.1016/j.jhep.2009.10.033", "20185200"]}, {"Citation": "Noordeen F. Hepatitis B virus infection: an insight into infection outcomes and recent treatment options. Virusdisease. 2015;26:1\u20138. doi: 10.1007/s13337-015-0247-y.", "ArticleIdList": ["10.1007/s13337-015-0247-y", "PMC4585049", "26436115"]}, {"Citation": "Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 1996;24:996\u20131002. doi: 10.1002/hep.510240504.", "ArticleIdList": ["10.1002/hep.510240504", "8903366"]}, {"Citation": "Shin MS, Kang EH, Lee YI. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res. 2005;67:163\u2013168. doi: 10.1016/j.antiviral.2005.06.005.", "ArticleIdList": ["10.1016/j.antiviral.2005.06.005", "16118024"]}, {"Citation": "Siddiqui MH, Alamri SA, Al-Whaibi MH, Hussain Z, Ali HM, El-Zaidy ME. A mini-review of anti-hepatitis B virus activity of medicinal plants. Biotechnol Biotechnol Equip. 2017;31:9\u201315. doi: 10.1080/13102818.2016.1240593.", "ArticleIdList": ["10.1080/13102818.2016.1240593"]}, {"Citation": "Soltan MM, Zaki AK. Antiviral screening of forty-two Egyptian medicinal plants. J Ethnopharmacol. 2009;126:102\u2013107. doi: 10.1016/j.jep.2009.08.001.", "ArticleIdList": ["10.1016/j.jep.2009.08.001", "19666102"]}, {"Citation": "Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16. doi: 10.1186/1745-6673-2-16.", "ArticleIdList": ["10.1186/1745-6673-2-16", "PMC2222591", "18053152"]}, {"Citation": "Utsunomiya T, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. Glycyrrhizin (20\u03b2-carboxy-11-oxo-30-norolean-12-en-3\u03b2-yl-2-O-\u03b2-d-glucopyranuronosyl-\u03b1-d-glucopyranosiduronic acid) improves the resistance of thermally injured mice to opportunistic infection of herpes simplex virus type 1. Immunol Lett. 1995;44:59\u201366. doi: 10.1016/0165-2478(94)00183-R.", "ArticleIdList": ["10.1016/0165-2478(94)00183-R", "7721345"]}, {"Citation": "Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int. 2014;2014:186864. doi: 10.1155/2014/186864.", "ArticleIdList": ["10.1155/2014/186864", "PMC4022204", "24877064"]}]}], "History": [{"Year": "2017", "Month": "12", "Day": "27"}, {"Year": "2018", "Month": "4", "Day": "17"}, {"Year": "2019", "Month": "1", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "5", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "5", "Day": "17"}], "PublicationStatus": "epublish", "ArticleIdList": ["30607323", "PMC6314789", "10.1007/s40203-018-0047-3", "47"]}}]}